Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis-Reference-Cited by-同舟云学术

Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis

Published:2023-09 Issue: Volume: Page:
ISSN:1076-6332
Container-title:Academic Radiology
language:en
Short-container-title:Academic Radiology

Author:

Zhang Jin-Xing,Hua Hong-jin,Cheng Yuan,Liu Sheng,Shi Hai-Bin,Zu Qing-Quan

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging

Reference29 articles.

1. Hepatocellular carcinoma;Forner;Lancet,2018

2. A global view of hepatocellular carcinoma: trends, risk, prevention and management;Yang;Nat Rev Gastroenterol Hepatol,2019

3. Hepatocellular carcinoma;Villanueva;N Engl J Med,2019

4. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements;Kudo;Liver Cancer,2020

5. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline;Gordan;J Clin Oncol,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current research status of transarterial therapies for hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-09-15

2. Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-07-15

3. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis;Academic Radiology;2024-05

4. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma;BMC Cancer;2024-03-27

5. Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial;Chinese Journal of Cancer Research;2024